Latest Articles

Publication Date
Clinical Application of Cell Therapy in the Treatment of Female Reproductive Diseases: A Systematic Review.

Reproductive disorders affect millions of women worldwide, playing a crucial role in determining female fertility health and quality of life. Conventional methods such as surgery, hormone therapy, and assisted reproductive …

Published: Sept. 23, 2025, midnight
Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.

People with endometriosis report consuming cannabis to manage their endometriosis symptoms, however, its efficacy has not been established in clinical studies. This study aimed to determine the feasibility, acceptability, and …

Published: Sept. 23, 2025, midnight
Potential Changes in the Eutopic Endometrium in Endometriosis: A Narrative Review.

Endometriosis is a disease characterized by the presence of ectopic endometrium, mainly within the peritoneal cavity, and is associated with the development of inflammation due to cyclic endometrial alterations. The …

Published: Sept. 22, 2025, midnight
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Sept. 16, 2025, 3:39 p.m.
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com

Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com

Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail

Published: Aug. 6, 2025, 1:11 p.m.
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Disparities in Racial and Ethnic Representation in Clinical Trials for FDA-Approved Treatments of Endometriosis.

Published: July 23, 2025, midnight
The Role of Plant-Based Diets and Personalized Nutrition in Endometriosis Management: A Review.

Endometriosis is a chronic, estrogen-dependent inflammatory condition that affects multiple organ systems and significantly impairs the quality of life in women of reproductive age. While conventional hormonal therapies may alleviate …

Published: July 13, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!